1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

MDIC Quality Summit Unveils New Risk-Based Framework, ‘Safe Space’ Recall Initiative

 
• By Brian Bossetta

During a recent summit, the Medical Device Innovation Consortium Case for Quality Collaborative Community introduced a new risk-based CAPA framework that moves away from the current compliance-focused “one-size-fits-all” approach to a more comprehensive strategy. The summit also discussed how the industry can more effectively and quickly notify consumers about recalls.

Summit
• Source: Shutterstock

Making any regulatory matter “cool” may seem impossible, especially in the realm of quality assurance. But not according to Kathryn Merrill, global quality program director at Medtronic. For the last five years, Merrill has led an initiative from the Medical Device Innovation Consortium (MDIC) with the goal of changing the way device industry views corrective and preventative actions (CAPA) — or, making CAPA cool.

Launched in 2018, #makeCAPAcool is an attempt to improve CAPA strategies by recasting the often-arduous process as part of a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Brazil’s Medtechs Look To Solutions After 50% US Tariff Hit Amid ‘Scenario Of Uncertainty’

 
• By Bernard Murphy

Hopes that last-minute negotiations might exempt Brazil’s $300m medtech exports from the latest round of US tariffs have been dashed, leaving the industry braced for further market instability that countermeasures could trigger.

Survey Reveals Gaps In Medtech Compliance Processes

 
• By Elizabeth Orr

Medical device firms often have serious compliance gaps, a recent Veeva MedTech survey found. Only 50% of the companies surveyed are confident in their global registration data, with 70% reporting inconsistencies during audits. The report recommends automation and better data governance.

Environmental Group Questions FDA’s Stance On PFAS In Medical Devices

 
• By Brian Bossetta

The US FDA says PFAS used in medical devices are safe and that there’s no reason to restrict them in device production. An environmental group finds the agency’s assertion questionable.